EVO Payments (EVOP) Tops Q4 EPS by 5c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus, FY20 EPS Mid-Point Views Below Consensus

EVO Payments (NASDAQ: EVOP) reported Q4 EPS of $0.24, $0.05 better than the analyst estimate of $0.19. Revenue for the quarter came in at $160.03 million versus the consensus estimate of $159.51 million.

“We are pleased with our fourth quarter and 2019 financial results,” said James G. Kelly, Chief Executive Officer of EVO. “Our 2019 results reflect the strong diversification and expanding distribution capabilities of our business. During 2019, we were able to increase our distribution and deliver growth via our international bank partnerships and our tech-enabled division across all markets. We augmented our ISV and B2B capabilities in 2019 through acquisitions in Mexico, the U.S., and Europe. We look forward to expanding our B2B, ISV, and international eCommerce businesses in 2020, as we continue to enable digital payments around the globe.”

GUIDANCE:

EVO Payments sees FY2020 EPS of $0.71-$0.74, versus the consensus of $0.74. EVO Payments sees FY2020 revenue of $516-526 million, versus the consensus of $646.48 million.

• We are providing 2020 guidance that includes the adoption of ASC 606; going forward, we will report revenue on a basis that includes the adoption of ASC 606. We expect 2020 full-year GAAP revenue to range from $516 million to $526 million. On a constant currency basis, we expect revenue growth to be 7% to 9% over 2019 results. Pre-tax income, on a GAAP basis, is expected to range from $17 million to $22 million compared to a pre-tax loss of $19 million in 2019. Adjusted EBITDA is expected to be in the range of $173 million to $179 million, reflecting growth of 10% to 13% over currency-neutral 2019 adjusted EBITDA. The adjusted EBITDA margin is expected to range from 33.5% to 34.0%, reflecting expansion of 80 to 130 basis points over the 2019 currency-neutral adjusted EBITDA margin.

For earnings history and earnings-related data on EVO Payments (EVOP) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Allarity reports Q2 2026 results, completes stenoparib manufacturing
• Nkarta Inc. (NKTX) PT Lowered to $10 at Stifel as Ntrust-1/2 Trial Enrollment Progresses